FDA-approved2Evidence: Large human trialsMetabolic and weight · Heart and blood vessels

Albiglutide1,2

Also called Tanzeum2

Key takeaway

Albiglutide is a GLP-1 receptor agonist made by joining GLP-1 analogue peptides to human albumin, and was the active ingredient in Tanzeum.1,3 FDA approved Tanzeum in 2014, but Drugs@FDA lists it as discontinued.2 In the Harmony Outcomes trial of 9,463 people with type 2 diabetes and cardiovascular disease, it reduced major cardiovascular events compared with placebo (7% versus 9%). Albiglutide is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.3,6

Albiglutide at a glance

What it isA GLP-1 receptor agonist fusion protein, in which GLP-1 analogue peptides are fused to human albumin, recorded by FDA’s substance registry as albiglutide.1
FDA statusFDA-approved, but discontinued. Drugs@FDA lists Tanzeum, application 125431, with an original approval date of April 15, 2014, and lists it as discontinued.2
Human evidenceHarmony Outcomes, a double-blind, randomized, placebo-controlled trial in 9,463 people with type 2 diabetes and cardiovascular disease.3
Evidence strengthLarge randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned

What is albiglutide?

Albiglutide is a GLP-1 receptor agonist in which copies of a GLP-1 analogue peptide are fused to human albumin, according to FDA’s substance registry.1

In the United States it was the active ingredient of Tanzeum, application 125431, according to Drugs@FDA.2

How does albiglutide work?

It activates the GLP-1 receptor. The Harmony Outcomes report notes that GLP-1 receptor agonists differ in chemical structure, duration of action and effects on clinical outcomes.1,3

What do human studies show?

Harmony Outcomes randomly assigned 9,463 people aged 40 and over with type 2 diabetes and cardiovascular disease to albiglutide or placebo, alongside standard care, and followed them for a median of 1.6 years.3

Cardiovascular death, heart attack or stroke occurred in 338 people (7%) on albiglutide and 428 (9%) on placebo, a hazard ratio of 0.78. Rates of acute pancreatitis, pancreatic cancer and other serious adverse events did not differ between groups.3

What the evidence base contains

  • Large randomized human trial Harmony Outcomes (NCT02465515): a double-blind, randomized, placebo-controlled trial at 610 sites in 28 countries in 9,463 people with type 2 diabetes and cardiovascular disease, in which the composite of cardiovascular death, heart attack or stroke occurred in 7% on albiglutide and 9% on placebo.3

Evidence-strength label: Large randomized human trials. How this label is assigned

Is albiglutide FDA-approved?

Yes, but Drugs@FDA lists Tanzeum, application 125431, as discontinued. The application’s original approval date is April 15, 2014.2

FDA’s compounding safety-risk page, current as of April 22, 2026, does not list albiglutide.4

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Albiglutide is not among them.5,6

Timeline

  1. FDA approves Tanzeum, application 125431, according to Drugs@FDA.2
  2. The Harmony Outcomes trial of albiglutide in 9,463 people is published.3

What is still unknown?

Why it was discontinued: Drugs@FDA lists its status but the records reviewed here give no reason.2

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Albiglutide: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Albiglutide are a bounded selection, not every registration or paper about Albiglutide. For the years before Albiglutide was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Albiglutide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Albiglutide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Tanzeum; discontinued. In the Harmony Outcomes trial of 9,463 people with type 2 diabetes and cardiovascular disease, it reduced major cardiovascular events compared with placebo. Albiglutide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Albiglutide?

FDA-approved as Tanzeum; discontinued. In the Harmony Outcomes trial of 9,463 people with type 2 diabetes and cardiovascular disease, it reduced major cardiovascular events compared with placebo. Albiglutide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗

The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
3
Source years
8
Drugs@FDA applications
1

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Albiglutide?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

19Selected dated records
25Connected citations
8Populated source years2014–2021
3/4Record lanes present

Registered human studies

Trial composition

13 of 13 selected trial records include at least one phase value; 13 of 13 include a status value in the retained structured contract.

PhasesPhase 3 8Phase 1 3Phase 2 2
Status at observationCompleted 13

PubMed bibliography

Publication composition

4 of 4 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 4Clinical Trial, Phase II 1Comparative Study 1Multicenter Study 1Randomized Controlled Trial 1Research Support, Non-U.S. Gov't 1Review 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
1
FDA Federal Register documents
1
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
19

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 19 dated records

Research hub

Explore the Albiglutide evidence record

Open all 19 records →
19Dated records
3Evidence types
19Cited public sources
8Source years

Change ledger

Recently changed for Albiglutide

Open all 19 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

Federal Register notice 2016-13797

The Federal Register published notice 2016-13797, attributed to FDA and its parent HHS department, on 2016-06-10. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; TANZEUM,” and PeptideScanner's exact reviewed identity mapping connects the document to Albiglutide.

PeptideScanner change date
November 17, 2026
Cited source date
June 10, 2016
Evidence lane
Regulatory
Record added

ClinicalTrials.gov record NCT00838903

PeptideScanner retained ClinicalTrials.gov record NCT00838903 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide.

PeptideScanner change date
November 16, 2026
Cited source date
January 9, 2017
Evidence lane
Clinical trials

Official-source collections

Source records for Albiglutide

Open the full research atlas →
PubMed4

4 with attributed title, venue, publication-date, and type metadata.

  1. Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes.The Journal of clinical endocrinology and metabolism · 2020 Jun 01
  2. Albiglutide (Tanzeum) for Diabetes Mellitus.American family physician · 2017 Apr 15
  3. Albiglutide for the treatment of type 2 diabetes mellitus.The Nurse practitioner · 2017 Feb 12
Explore all selected literature →
ClinicalTrials.gov13

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT02229227Registry update November 27, 2020 · completed at observation
  2. NCT00938158Registry update July 21, 2017 · completed at observation
  3. NCT01077505Registry update June 14, 2017 · completed at observation
Explore all selected trial records →Explore all public record history →

Evidence types

Coverage by source year

Selected records span April 15, 2014 to February 1, 2021. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration1,2
  • U.S. Department of Health and Human Services5
Dated updates connected to this profile · 19

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes.↗

    PubMed lists PMID 32219329 in The Journal of clinical endocrinology and metabolism as Clinical Trial, Phase II, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, and 1 more PubMed publication type, with publication-date metadata of 2020-06-01 (day precision). PeptideScanner associated the retained record with the identity slug albiglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT02229227↗

    PeptideScanner retained ClinicalTrials.gov record NCT02229227 at 2026-11-16T17:45:42.793Z. Its registry update date was 2020-11-27, and PeptideScanner's reviewed identity mapping was albiglutide.↗

  3. Literature metadata

    Albiglutide for the treatment of type 2 diabetes mellitus.↗

    PubMed lists PMID 28085780 in The Nurse practitioner as Journal Article, with publication-date metadata of 2017-02-12 (day precision). PeptideScanner associated the retained record with the identity slug albiglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Literature metadata

    Albiglutide (Tanzeum) for Diabetes Mellitus.↗

    PubMed lists PMID 28409609 in American family physician as Journal Article, Review, with publication-date metadata of 2017-04-15 (day precision). PeptideScanner associated the retained record with the identity slug albiglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT00938158↗

    PeptideScanner retained ClinicalTrials.gov record NCT00938158 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-07-21, and PeptideScanner's reviewed identity mapping was albiglutide.↗

  6. Clinical trials

    ClinicalTrials.gov record NCT01077505↗

    PeptideScanner retained ClinicalTrials.gov record NCT01077505 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-06-14, and PeptideScanner's reviewed identity mapping was albiglutide.↗

  7. Clinical trials

    ClinicalTrials.gov record NCT01406262↗

    PeptideScanner retained ClinicalTrials.gov record NCT01406262 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-06-08, and PeptideScanner's reviewed identity mapping was albiglutide.↗

  8. Clinical trials

    ClinicalTrials.gov record NCT01777282↗

    PeptideScanner retained ClinicalTrials.gov record NCT01777282 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-05-03, and PeptideScanner's reviewed identity mapping was albiglutide.↗

  9. Clinical trials

    ClinicalTrials.gov record NCT01098539↗

    PeptideScanner retained ClinicalTrials.gov record NCT01098539 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-02-28, and PeptideScanner's reviewed identity mapping was albiglutide.↗

  10. Clinical trials

    ClinicalTrials.gov record NCT01098461↗

    PeptideScanner retained ClinicalTrials.gov record NCT01098461 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-13, and PeptideScanner's reviewed identity mapping was albiglutide.↗

  11. Clinical trials

    ClinicalTrials.gov record NCT01475734↗

    PeptideScanner retained ClinicalTrials.gov record NCT01475734 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-11, and PeptideScanner's reviewed identity mapping was albiglutide.↗

  12. Clinical trials

    ClinicalTrials.gov record NCT00838903↗

    PeptideScanner retained ClinicalTrials.gov record NCT00838903 at 2026-11-16T17:45:42.793Z. Its registry update date was 2017-01-09, and PeptideScanner's reviewed identity mapping was albiglutide.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Albiglutide substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 16, 2026

  2. 2
    Drugs@FDA: TANZEUM (albiglutide), application 125431 · original approval April 15, 2014 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  3. 3
    Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial (2018) · PMID 30291013 ↗

    The Lancet · Official source · Source checked November 16, 2026

  4. 4
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  5. 5
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  6. 6
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026